With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

After rising to prominence during the COVID-19 pandemic, South African drugmaker Aspen Pharmacare has landed in the FDA's ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

Activist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for ...

After a federal guilty plea in 2020, the former OxyContin drugmaker is required to reemerge from Chapter 11 bankruptcy as a ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...